The Wyss Center for Bio and Neuroengineering and the Swiss technology company Coat-X have announced a collaboration to bring to market a new ultra-thin, biocompatible coating for use in active medical implants.
Jonathan IMHOF
At 10 microns thick, the flexible coating conforms to the shape of the electronics, encasing them directly in a leakproof, biocompatible envelope.
Active implants, such as cardiac pacemakers, cochlear implants and neural monitoring or stimulation devices, contain sensitive electronics that must be protected from the warm, wet, and salty environment of the human body.
George Kouvas, chief technology officer at the Wyss Center said: “Despite advances in the microfabrication of electronics, active implants today still have relatively large volumes. This is mainly due to the limited scalability of traditional medical implant housing technologies. The electronics may shrink but this is not the case for their housings. Our partnership with Coat-X will validate the use of a new, thin-film coating technology, paving the way for the miniaturisation of medical implants and enabling a future where very small medical devices are seamlessly integrated with the human body.”
The collaboration will bring materials engineers from Coat-X together with the Wyss Center’s electromechanical team.
Andreas Hogg, CEO at Coat-X, said: “We will apply Coat-X’s multilayer encapsulation technology in active medical implants, such as next generation electrodes and electronics. We will start by using a custom-built accelerated aging system at the Wyss Center to verify the long-term performance of our coating technology in the human body.”
The team will develop and coat prototype devices with several variations of the encapsulation technology and then will subject them to high temperatures and humidity to accelerate their ageing. Electronic tags built into the devices will wirelessly send updates on the internal status of the electronics, continuously assessing the hermeticity of the new coating and giving valuable information on its performance and reliability in the body.
Wyss Center CEO, Mary Tolikas, said: “If we can validate that Coat-X’s ultra-thin coating has favourable barrier and durability properties in the long term, we will further our collaboration to bring this technology to market and, hopefully, enable even smaller medical devices to be implanted in patients around the world.”
